Targeting the Interactions Between Disordered Iron Homeostasis and Mineral Metabolism in Chronic Kidney Disease (Aim 1)

NCT03073369 Phase 4 WITHDRAWN

The purpose of the study is to learn more about how treatment with vitamin D can affect iron metabolism and blood levels of hepcidin (hormone controlling iron levels) in people with chronic kidney disease (CKD). Iron is an essential mineral which is a major component of proteins that carry oxygen in the blood. Problems with iron metabolism can lead to low blood levels (anemia), which can commonly happen in people with CKD. New research over the last decade has uncovered a new hormone called 'hepcidin', which is made in the liver and released into the blood. Hepcidin controls how much iron is in the blood by preventing the absorption of iron from food. Blood levels of hepcidin C are found to be high in people with CKD, and a recent small study in people with normal kidney function showed that treatment with vitamin D decreased hepcidin levels. In this study, investigators would like to examine the effects of vitamin D (Ergocalciferol) on iron metabolism and blood levels of hepcidin in individuals with CKD.

Details

Lead sponsor	University of Alabama at Birmingham
Phase	Phase 4
Status	WITHDRAWN
Start date	2018-01-01
Completion	2018-12

Conditions

• CKD
• Chronic Kidney Diseases
• Hepcidin
• Ergocalciferol
• Vitamin D
• Iron-deficiency
• Anemia

Interventions

• Ergocalciferol 50000 UNT
• Placebo

Primary outcomes

• Change in serum hepcidin levels — At Day 0, Day 3, 1 week, 4 weeks and 6 weeks
  Difference in change in serum hepcidin levels (ng/ml) over time between the two groups

Countries

United States